Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +38.25%
#3 Solv Protocol xSolvBTC Solv Protocol xSolvBTC +22.79%
#4 Cysic Cysic +18.33%
#5 Nockchain Nockchain +17.91%
#6 Bedrock Bedrock +17.41%
#7 Velvet Velvet +14.00%
#8 Perle Perle +13.44%
#9 Fabric Protocol Fabric Protocol +12.53%
#10 Versatize Coin Versatize Coin +12.50%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Roquefort Therapeutics plc Roquefort Therapeutics plc

Roquefort Therapeutics plc

ROQ
Rank in Stocks #37956
Roquefort Therapeutics plc functions as a biotechnology firm, focusing its... Roquefort Therapeutics plc functions as a biotechnology firm, focusing its efforts on the discovery and development of innovative pharmaceutical treatments. The company's primary research objective is to develop therapies that target Midkine, a circulating growth factor protein and pro-inflammatory mediator, for applications in cancer treatment. Established in 2020, Roquefort Therapeutics plc has its main operations based in London, United Kingdom.
Share Price
$0.10205262
Last synced: 2026-04-23
Market Cap
$1.32M
Change (1 day)
5.19%
Change (1 year)
-54.38%
Country
GB
Trade Roquefort Therapeutics plc (ROQ)

Category

Healthcare
P/E ratio for Roquefort Therapeutics plc (ROQ)
P/E ratio as of 2026 TTM: 0
According to Roquefort Therapeutics plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Roquefort Therapeutics plc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.